- 0208 903 4819
- Weekday Hours: 10AM - 5PM
One of the most prevalent adverse effects of perimenopause and menopause, affecting at least 50% of women, is weight gain. Research from the SWAN and Healthy Women’s studies indicates that women gain roughly 1.5 kg annually throughout perimenopause, adding up to an average weight gain of 10kg by the time they approach menopause.
One of the most prevalent adverse effects of perimenopause and menopause, affecting at least 50% of women, is weight gain. Research from the SWAN and Healthy Women’s studies indicates that women gain roughly 1.5 kg annually throughout perimenopause, adding up to an average weight gain of 10kg by the time they approach menopause.
Semaglutide may be useful in managing menopausal weight gain, according to
studies. Patients on semaglutide who took a weekly dose of 2.4 mg for 68
weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their
body weight, compared to 2.4% for the placebo group.
Semaglutide may be useful in managing menopausal weight gain, according to
studies. Patients on semaglutide who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group.
Semaglutide, a medication for type 2 diabetes, is marketed under the name Wegovy. Semaglutide are members of the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. These drugs imitate the functions of the GLP-1 hormone, which aids in controlling body weight, food consumption, and hunger. By slowing down the time it takes to digest the food consumed, it makes the person feel fuller for longer which in turn reduces food intake. This accompanied with a healthy lifestyle will lead to successful weight loss outcomes.
Semaglutide may be useful in managing menopausal weight gain, according to studies.
Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months,
dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the
placebo group. People who took Ozempic in conjunction with good lifestyle practices like
exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different
research done by Novo Nordisk, the company that makes semaglutide.
Semaglutide may be useful in managing menopausal weight gain, according to studies. Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group. People who took Ozempic in conjunction with good lifestyle practices like exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different research done by Novo Nordisk, the company that makes semaglutide.
Read our articles on Wegovy & Mounjaro if you would like to learn more about the benefits, the research and case studies.
Videos created by our chief doctor on managing and understanding Wegovy to help you achieve the best outcomes possible.
Book an Appointment Today
All consultations and prescriptions are carried out by GMC registered medical practitioners.
All dispensing and shipping of medicines are completed by a UK licensed, GPhC registered Pharmacy no: 9011284.
CloudRx is our partner pharmacy and prescribing service.
*Disclaimer: Results may vary from person to person depending on individual engagement and commitment to the programme.
The content of this website is provided for general informational purposes only and is not intended as, nor should it be considered a substitute for, professional medical advice. Do not use the information on this website for diagnosing or treating any medical or health related condition. If you have or suspect you have a medical problem, promptly contact your healthcare provider.
© 2023 The London Obesity Clinic
